Sheng Cui - NewAmsterdam Pharma Chief Officer
| NAMS Stock | 19.85 0.95 4.57% |
Executive
Sheng Cui is Chief Officer of NewAmsterdam Pharma
| Address | Gooimeer 2-35, Naarden, Netherlands, 1411 DC |
| Phone | 31 35 206 2971 |
| Web | https://www.newamsterdampharma.com |
NewAmsterdam Pharma Management Efficiency
The company has return on total asset (ROA) of (0.2927) % which means that it has lost $0.2927 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4737) %, meaning that it created substantial loss on money invested by shareholders. NewAmsterdam Pharma's management efficiency ratios could be used to measure how well NewAmsterdam Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.54 in 2024. Return On Capital Employed is likely to gain to -0.53 in 2024. At this time, NewAmsterdam Pharma's Net Tangible Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 36.8 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 290.7 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Andrew Schwendenman | Replimune Group | 48 | |
| Eric MBA | PureTech Health PLC | N/A | |
| Kristina Meyer | Inventiva Sa | N/A | |
| Gregory Perry | Merus BV | 64 | |
| Afsaneh Mohebbi | PepGen | N/A | |
| MD MBA | Molecular Partners AG | N/A | |
| Minori MD | Compass Therapeutics | 61 | |
| Neil CPA | Compass Therapeutics | 57 | |
| III JD | PureTech Health PLC | N/A | |
| Cindy Berejikian | Mineralys Therapeutics, Common | N/A | |
| Mary Fenton | Cullinan Oncology LLC | 60 | |
| Robert McKean | Mineralys Therapeutics, Common | N/A | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Philip JD | Monte Rosa Therapeutics | 45 | |
| Christopher Sarchi | Replimune Group | 55 | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| Michael Deperro | Rezolute | N/A | |
| Cheryl Murphy | PureTech Health PLC | N/A | |
| Mary JD | PepGen | 56 | |
| Brenda Vreeswyk | Janux Therapeutics | N/A | |
| David MD | Mineralys Therapeutics, Common | 69 | |
Management Performance
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 |
NewAmsterdam Pharma Leadership Team
Elected by the shareholders, the NewAmsterdam Pharma's board of directors comprises two types of representatives: NewAmsterdam Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NewAmsterdam. The board's role is to monitor NewAmsterdam Pharma's management team and ensure that shareholders' interests are well served. NewAmsterdam Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NewAmsterdam Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Louise Kooij, Treasurer, CFO | ||
| Jim Jacobson, Chief Secretary | ||
| Annie Neild, VP Affairs | ||
| FESC MD, Chief Founder | ||
| Marc MD, Chief Officer | ||
| MSc MBA, Chief Officer | ||
| Lina Gugucheva, Chief Officer | ||
| Sheng Cui, Chief Officer | ||
| Douglas Kling, Chief Officer | ||
| FACC Facp, President CEO | ||
| Bob Rambo, Executive Marketing | ||
| MBA Jones, Chief Officer | ||
| FACC Facc, President, CEO | ||
| Mayur Somaiya, Chief Officer | ||
| Matthew Philippe, Executive Relations |
NewAmsterdam Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NewAmsterdam Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (0.86) % | ||||
| Current Valuation | 1.41 B | ||||
| Shares Outstanding | 92.39 M | ||||
| Shares Owned By Insiders | 0.25 % | ||||
| Shares Owned By Institutions | 84.04 % | ||||
| Number Of Shares Shorted | 1.01 M | ||||
| Price To Book | 4.84 X | ||||
| Price To Sales | 57.20 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.